Company / Net Income
NewAmsterdam Pharma Co N.V. Net Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$203.8M
FY2025
5-year range
-$241.6M / -$22.6M
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
#156 of 215
Health Care
What the data says
At -$204M, NewAmsterdam Pharma Co N.V.'s net income ranks #156 of 215 in the Health Care sector. Net Income returned to growth in FY2025 after 2 years of decline, reaching -$204M.
Based on SEC 10-K filings.
-$204M in FY2025.
Declined from -$177M to -$204M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#156 of 215 in Health CareTop 73% of 215This company -$203.8M Sector average $431.3M
▼
-147.3% below sector average
Key checks
Key Insights
- In FY2025, net income increased 15.6% year-over-year.
- Ranks #156 out of 215 companies in the Health Care sector.
- Peak net income was recorded in FY2022.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$203.8M | +15.6% |
| FY2024 | -$241.6M | -36.5% |
| FY2023 | -$176.9M | -681.7% |
| FY2022 | -$22.6M | +45.8% |
| FY2021 | -$41.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026